Medidata Solutions (MDSO) Stock Rating Upgraded by BidaskClub
BidaskClub upgraded shares of Medidata Solutions (NASDAQ:MDSO) from a buy rating to a strong-buy rating in a research report sent to investors on Thursday.
MDSO has been the subject of a number of other research reports. Dougherty & Co restated a buy rating and set a $89.00 target price (up previously from $79.00) on shares of Medidata Solutions in a report on Thursday, May 10th. Royal Bank of Canada upgraded Medidata Solutions from a sector perform rating to an outperform rating and set a $100.00 target price for the company in a report on Tuesday, July 17th. Zacks Investment Research lowered Medidata Solutions from a hold rating to a sell rating in a report on Thursday, June 21st. JPMorgan Chase & Co. lowered Medidata Solutions from an overweight rating to a neutral rating and set a $87.00 target price for the company. in a report on Tuesday, July 24th. Finally, ValuEngine lowered Medidata Solutions from a buy rating to a hold rating in a report on Tuesday, July 24th. One research analyst has rated the stock with a sell rating, six have issued a hold rating, eight have assigned a buy rating and one has issued a strong buy rating to the stock. The stock presently has a consensus rating of Buy and an average target price of $86.93.
Medidata Solutions stock opened at $78.21 on Thursday. The company has a quick ratio of 1.41, a current ratio of 1.41 and a debt-to-equity ratio of 0.16. The firm has a market cap of $4.63 billion, a price-to-earnings ratio of 92.01, a P/E/G ratio of 4.87 and a beta of 1.40. Medidata Solutions has a twelve month low of $59.60 and a twelve month high of $88.87.
In other news, Director Robert Taylor sold 3,630 shares of the stock in a transaction on Monday, June 4th. The stock was sold at an average price of $78.70, for a total transaction of $285,681.00. Following the completion of the sale, the director now owns 49,036 shares in the company, valued at approximately $3,859,133.20. The sale was disclosed in a document filed with the SEC, which is accessible through the SEC website. Also, CFO Rouven Bergmann sold 3,000 shares of the stock in a transaction on Tuesday, June 19th. The shares were sold at an average price of $82.85, for a total value of $248,550.00. Following the sale, the chief financial officer now owns 81,642 shares of the company’s stock, valued at approximately $6,764,039.70. The disclosure for this sale can be found here. In the last quarter, insiders have sold 36,418 shares of company stock valued at $2,860,168. Company insiders own 4.70% of the company’s stock.
Institutional investors and hedge funds have recently modified their holdings of the company. Millennium Management LLC acquired a new position in shares of Medidata Solutions in the 4th quarter valued at $2,467,000. Joel Isaacson & Co. LLC acquired a new position in shares of Medidata Solutions in the 1st quarter valued at $314,000. Comerica Bank increased its position in shares of Medidata Solutions by 9.3% in the 1st quarter. Comerica Bank now owns 61,772 shares of the company’s stock valued at $4,537,000 after acquiring an additional 5,250 shares during the period. Sumitomo Mitsui Trust Holdings Inc. acquired a new position in shares of Medidata Solutions in the 1st quarter valued at $26,769,000. Finally, Kornitzer Capital Management Inc. KS increased its position in shares of Medidata Solutions by 17.1% in the 1st quarter. Kornitzer Capital Management Inc. KS now owns 161,900 shares of the company’s stock valued at $10,169,000 after acquiring an additional 23,665 shares during the period.
Medidata Solutions Company Profile
Medidata Solutions, Inc provides cloud-based solutions for life sciences worldwide. It offers the Medidata Clinical Cloud, a platform, pioneering analytics, and clinical technology for the development of new therapies. The company's platform solutions include data capture and management and trial planning and management.
Further Reading: New Google Finance Tool and Screening Stocks
Receive News & Ratings for Medidata Solutions Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Medidata Solutions and related companies with MarketBeat.com's FREE daily email newsletter.